NRXN1 and autism: Research investigating multilevel brain and neurocognitive markers of NRXN1 deletions and PMD aligned to preclinical models is one of the ongoing aims of the AIMS-2-TRAILS consortium (Cooke et al., 2022), which is more broadly focused on understanding the heterogeneity and developmental trajectories of autism, as well as identifying biomarkers and testing efficacy of new treatments.